U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
A new study shows risks for premature death associated with CUD. Others show increased memory problems, CUD, depression, ...
A new cohort study found that schizophrenia cases related to cannabis use disorder serious enough to warrant a person to seek emergency care increased afte ...
“If cannabis use ‘causes’ schizophrenia, it is absolutely impossible that the rate of schizophrenia would not be going up ...
Medical Xpress on MSN10d
Rising cannabis use disorder cases contribute to growing schizophrenia diagnosesThe proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...
Cannabis is gaining widespread appeal and a growing number of U.S. states are approving medical marijuana. A large study ...
Nevertheless, the authors note that heavy cannabis use does worsen symptoms and the prognosis ... cases associated with a cannabis use disorder over the past 17 years and rising cases of psychosis ...
The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal ...
The proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...
Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of marijuana, ...
In people with treatment-resistant depression, investigational inhalable mebufotenin yielded a 15.5-point placebo-adjusted ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback